Resistant Hypertension Optimal Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Resistant hypertension (ReHy) is an emerging clinical and public health problem which tends to increase because populations are living longer and there is a growing global epidemic of obesity, diabetes and sleep apnea. It is also tempting to speculate that the excessive dietary salt ingestion reported in many countries can contribute substantially to the risk of ReHy development. ReHy is defined as persistent high blood pressure (above the target goal) in spite of the use of at least 3 antihypertensive agents of different classes, one of them must being diuretics.

Data regarding the exact prevalence of ReHy are very limited. In addition, little data is available about 3-drug combinations but a simplified treatment algorithm has demonstrated that a combination of a diuretic plus an angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin-receptor blocker (ARB) plus diuretic, adding a calcium channel blocker when necessary, controlled 64% of hypertensive patients and, in addition, was even more efficient than the current guideline-based management. By contrast, the fourth drug to be added-on the triple regimen is still controversial and guided by empirical choices or personal preferences. Recent studies suggest the emerging role of spironolactone as the "first-line" fourth drug for treating resistant hypertension. Conversely, because of the pathophysiological rationale, others have proposed the use of β-blockers or even centrally acting agents for managing the sympathetic hyperactivity. The present concerns about the limited blood pressure reducing effect of β-blockers, especially in elderly people, the potent effect of centrally acting agents and our personal experience are pointing to clonidine as the fourth drug to be added-on to a multidrug combination for reaching optimal blood pressure in patients with ReHy. Nevertheless, no studies have been performed comparing, head-to-head, which one is the best fourth drug (spironolactone or clonidine) to be added-on to a common used multidrug combination in order to treat this condition.

Therefore, the principal objectives of the ReHOT Trial are to assess prospectively: (1) the prevalence of ReHy in a cohort of outpatients with stage II hypertension; (2) the effect of spironolactone on blood pressure, in comparison to clonidine, when added to a multidrug combination consisting of chlorthalidone plus ACEi (or ARB) plus amlodipine, all of 3 up-titrated to the highest dose; (3) the role of measuring sympathetic nervous system activity and renin-angiotensin-aldosterone activity on predicting the response of blood pressure to spironolactone and clonidine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vascular Dysfunction in Human Obesity Hypertension

NCT01983462

Obesity Prehypertension Hypertension

TERMINATED PHASE2

Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

NCT01850901

Hypertension Chronic Kidney Disease

COMPLETED PHASE3

Hypertension Screening and Treatment Program

NCT00007592

Hypertension

COMPLETED

Treatment of Hypertension

NCT00000484

Cardiovascular Diseases Heart Diseases Hypertension +1 more

COMPLETED PHASE3

Renal Denervation in Patients With Refractory Hypertension

NCT00753285

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spironolactone

Group Type ACTIVE_COMPARATOR

Spironolactone

Intervention Type DRUG

Spironolactone (titrating dose from 12.5 to 50mg SID)

Clonidine

Group Type ACTIVE_COMPARATOR

Clonidine

Intervention Type DRUG

Clonidine (titrating dose from 0.100-0.300mg BID)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spironolactone

Spironolactone (titrating dose from 12.5 to 50mg SID)

Intervention Type DRUG

Clonidine

Clonidine (titrating dose from 0.100-0.300mg BID)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged between 18 and 75
2. With systolic blood pressure\> 160 mmHg and \<220mmHg and / or diastolic\> 100 mmHg in the sitting position and according to Brazilian Guidelines on Hypertension (perform steps by obtaining two consecutive measurements differing by less than 4 mmHg between them, calibrated using a sphygmomanometer)
3. Patient regularly enrolled in participating center

Exclusion Criteria

1. Systolic blood pressure\> 220 mmHg
2. Patients with cardiovascular events (stroke, AMI, etc.). or cardiovascular procedures with less than 6 months of evolution
3. Renal stages IV and V (glomerular20 filtration estimated by MDRD formula \<30 ml / min; where MDRD = 186 x (S\_Cr) -1.154 x (age) -0.203 x (0.742 if fem.) x (1.210 if Afro-amer. ))
4. Heart failure class III and IV
5. History of malignant disease with life expectancy \< 2 years
6. Alcoholism
7. Psychiatric illnesses that prevent compliance with the Protocol
8. Women of childbearing age who are not in use of effective contraception
9. Pregnancy
10. Arrhythmias, valvular heart disease, AV block 2 and 3 degrees without MP
11. Hepatic impairment
12. Patients with a history of hypersensitivity to any of the drugs under study
13. Examination of the fundus: Grade III and Grade IV

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No